Leflunomide for the treatment of rheumatoid arthritis

Nancy Olsen, Vibeke Strand, Joel M. Kremer

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Leflunomide treatment appears to offer an alternative to methotrexate and sulfasalazine and is a welcome addition to the therapeutic armamentarium for treating active RA. Leflunomide treatment for more than 12 months results in clinically meaningful improvements in disease-specific measures of physical function. The phase 3 trials have shown leflunomide to be as effective as methotrexate and sulfasalazine and an option for initial DMARD therapy. As with all new agents, the long-term safety and value of leflunomide will be determined by use in the clinic.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalBulletin on the Rheumatic Diseases
Issue number8
StatePublished - Dec 1 1999

All Science Journal Classification (ASJC) codes

  • Rheumatology


Dive into the research topics of 'Leflunomide for the treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this